Stryker Co. (NYSE:SYK) Shares Sold by Park National Corp OH

Park National Corp OH reduced its stake in Stryker Co. (NYSE:SYK - Free Report) by 2.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 47,378 shares of the medical technology company's stock after selling 1,345 shares during the period. Park National Corp OH's holdings in Stryker were worth $17,636,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. J. W. Coons Advisors LLC increased its holdings in shares of Stryker by 0.7% in the fourth quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock worth $1,315,000 after purchasing an additional 26 shares during the last quarter. Mascoma Wealth Management LLC increased its stake in Stryker by 22.7% in the 4th quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock worth $53,000 after acquiring an additional 27 shares during the last quarter. Opal Wealth Advisors LLC increased its stake in Stryker by 1.6% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after acquiring an additional 28 shares during the last quarter. Lindbrook Capital LLC increased its position in Stryker by 2.0% in the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock worth $507,000 after purchasing an additional 28 shares during the last quarter. Finally, JFS Wealth Advisors LLC increased its position in Stryker by 4.4% in the fourth quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company's stock worth $247,000 after purchasing an additional 29 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Trading Up 0.1%

Shares of NYSE SYK traded up $0.51 during mid-day trading on Friday, reaching $382.86. The company had a trading volume of 1,993,145 shares, compared to its average volume of 1,342,825. The business's 50-day moving average is $368.77 and its 200-day moving average is $376.22. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock has a market cap of $146.13 billion, a price-to-earnings ratio of 49.34, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The company's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.50 EPS. Equities analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be paid a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.88%. Stryker's dividend payout ratio (DPR) is currently 45.41%.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 5.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Roth Mkm boosted their price target on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. JMP Securities restated a "market perform" rating on shares of Stryker in a report on Monday, May 5th. Needham & Company LLC reissued a "buy" rating and set a $442.00 price objective on shares of Stryker in a research note on Friday, March 21st. Truist Financial boosted their price objective on Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a research note on Monday, May 5th. Finally, BTIG Research set a $403.00 price objective on Stryker and gave the stock a "buy" rating in a research note on Monday, April 14th. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, Stryker has an average rating of "Moderate Buy" and an average target price of $427.30.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.